Literature DB >> 15801071

Association between systemic sclerosis and breast cancer: eight new cases and review of the literature.

David Launay1, Rozenn Le Berre, Pierre-Yves Hatron, Jean-Philippe Peyrat, Eric Hachulla, Bernard Devulder, Mohamed Hebbar.   

Abstract

Several studies have demonstrated an increased frequency of cancer in patients with systemic sclerosis (SSc), specially lung and breast cancers. The pathogenesis of the association between SSc and cancer is not fully established. The aim of this study was to describe new cases of the association between SSc and breast cancer and to perform a review of the literature. We retrospectively studied the medical files of eight patients followed in our institution for SSc and breast cancer. We analyzed them with data available in the literature for a total of 46 patients. Cutaneous extension of SSc was clearly mentioned in 17 cases: the SSc was limited in 10 cases and diffuse in 7 cases The median age at the diagnosis of cancer was 54 years (range: 40-71). The median duration between SSc onset and breast cancer diagnosis was 11.5 months (range: 0-288). The duration between SSc onset and breast cancer diagnosis was < or = 12 months in 27 of 44 patients (61.4%), and in 11 (25%) of them the diagnosis of both diseases was made simultaneously. It was clearly mentioned for 35 patients whether the diagnosis of breast cancer was made before or after the onset of SSc. The diagnosis of breast cancer was made before SSc onset in 17 of 35 patients (48.6%) and after SSc onset in 18 of 35 patients (51.4%). For 33 patients, the follow-up was available: 18 (54.5%) died, 11 (33.3%) of them within the 1st year after the diagnosis of the cancer. For none of the patients did the anticancer treatment improve the SSc. The close temporal relationship between SSc onset and breast cancer diagnosis is highly suggestive of a pathophysiological link. SSc is probably not a paraneoplastic disease since the anticancer treatment has no influence on the evolution of SSc. However, it can be suggested that SSc could be a disease facilitating breast cancer and/or metastases development.

Entities:  

Mesh:

Year:  2004        PMID: 15801071     DOI: 10.1007/s10067-004-0940-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  Radiation-induced localized scleroderma in breast cancer patients.

Authors:  N R Bleasel; K M Stapleton; C Commens; V A Ahern
Journal:  Australas J Dermatol       Date:  1999-05       Impact factor: 2.875

2.  [Systemic scleroderma and cancer. Search for predictive factors of cancer in 123 patients with scleroderma].

Authors:  X Kyndt; M Hebbar; V Queyrel; E Hachulla; P Y Hatron; B Devulder
Journal:  Rev Med Interne       Date:  1997-07       Impact factor: 0.728

3.  Identification of an inducible endothelial-leukocyte adhesion molecule.

Authors:  M P Bevilacqua; J S Pober; D L Mendrick; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin".

Authors:  H N Claman; R C Giorno; J R Seibold
Journal:  Arthritis Rheum       Date:  1991-12

5.  Incidence of cancer among patients with systemic sclerosis.

Authors:  A K Rosenthal; J K McLaughlin; G Gridley; O Nyrén
Journal:  Cancer       Date:  1995-09-01       Impact factor: 6.860

6.  Malignancy in progressive systemic sclerosis--association with breast carcinoma.

Authors:  P Lee; C Alderdice; S Wilkinson; E C Keystone; M B Urowitz; D D Gladman
Journal:  J Rheumatol       Date:  1983-08       Impact factor: 4.666

Review 7.  [Systemic scleroderma and cancers: 21 cases and review of the literature].

Authors:  P Bielefeld; P Meyer; D Caillot; S Dalac; P Camus; C Tavernier; G Couillaut; J M Chalopin; J F Besancenot
Journal:  Rev Med Interne       Date:  1996       Impact factor: 0.728

8.  High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F.

Authors:  J B Rattner; J Rees; C M Whitehead; C A Casiano; E M Tan; R L Humbel; K Conrad; M J Fritzler
Journal:  Clin Invest Med       Date:  1997-10       Impact factor: 0.825

9.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

10.  Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer.

Authors:  M A Recchi; M Hebbar; L Hornez; A Harduin-Lepers; J P Peyrat; P Delannoy
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

View more
  13 in total

1.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

Review 2.  Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 3.  Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications.

Authors:  Ami A Shah; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

Review 4.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

5.  Mechanistic and clinical insights at the scleroderma-cancer interface.

Authors:  Ami A Shah; Livia Casciola-Rosen
Journal:  J Scleroderma Relat Disord       Date:  2017-10-05

Review 6.  Comorbidity burden in systemic sclerosis: beyond disease-specific complications.

Authors:  Eleni Pagkopoulou; Alexandra Arvanitaki; Dimitrios Daoussis; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2019-07-12       Impact factor: 2.631

7.  Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.

Authors:  Ami A Shah; Laura K Hummers; Livia Casciola-Rosen; Kala Visvanathan; Antony Rosen; Fredrick M Wigley
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

Review 8.  Systemic Sclerosis Association with Malignancy.

Authors:  Gemma Lepri; Martina Catalano; Silvia Bellando-Randone; Serena Pillozzi; Elisa Giommoni; Roberta Giorgione; Cristina Botteri; Marco Matucci-Cerinic; Lorenzo Antonuzzo; Serena Guiducci
Journal:  Clin Rev Allergy Immunol       Date:  2022-09-19       Impact factor: 10.817

9.  Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study.

Authors:  Tim Y-T Lu; Catherine L Hill; Eliza K Pontifex; Peter J Roberts-Thomson
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

10.  Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.

Authors:  Pia Moinzadeh; Carmen Fonseca; Martin Hellmich; Ami A Shah; Cecilia Chighizola; Christopher P Denton; Voon H Ong
Journal:  Arthritis Res Ther       Date:  2014-02-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.